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Abstract
Background: Results of preclinical studies suggest that the GABAB receptor agonist baclofen may
be useful in treatment of opioid dependence. This study was aimed at assessing the possible efficacy
of baclofen for maintenance treatment of opioid dependence.
Methods: A total of 40 opioid-dependent patients were detoxified and randomly assigned to
receive baclofen (60 mg/day) or placebo in a 12-week, double blind, parallel-group trial. Primary
outcome measure was retention in treatment. Secondary outcome measures included opioids and
alcohol use according to urinalysis and self-report ratings, intensity of opioid craving assessed with
a visual analogue scale, opioid withdrawal symptoms as measured by the Short Opiate Withdrawal
Scale and depression scores on the Hamilton inventory.
Results: Treatment retention was significantly higher in the baclofen group. Baclofen also showed
a significant superiority over placebo in terms of opiate withdrawal syndrome and depressive
symptoms. Non-significant, but generally favorable responses were seen in the baclofen group with
other outcome measures including intensity of opioid craving and self-reported opioid and alcohol
use. However, no significant difference was seen in the rates of opioid-positive urine tests.
Additionally, the drug side effects of the two groups were not significantly different.
Conclusion: The results support further study of baclofen in the maintenance treatment of opioid
dependence.
Background
Recent preclinical studies offer support for the idea that a
number of GABAergic drugs, particularly baclofen, may
help promote abstinence from a variety of drugs of abuse
[1]. For example, many studies with rats have shown that
the GABAB  receptor agonist baclofen suppresses self-
administration of cocaine, ethanol, nicotine and metham-
phetamine [2-9]. Moreover, one study has reported that
baclofen reduces self-administration of heroin in rats [10]
and two other studies have shown that baclofen reduces
opioid withdrawal signs in morphine-dependent animals
[11,12].
Taken overall, these studies indicate that baclofen may be
effective in attenuating drug-associated positive and nega-
tive reinforcements. In positive reinforcement, a rewarding
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stimulus (e.g., drug-induced euphoria) directly increases
the probability of a response (e.g., continued drug use).
Neuroanatomically, the mesolimbic dopamine system
has been linked to the positive reinforcing effect of
cocaine, nicotine, heroin and ethanol. The primary por-
tion of this system appears to be a subset of dopaminergic
projections originating in the ventral tegmental area
(VTA) and terminating in the nucleus accumbens (NA)
(Fig. 1). Drugs of abuse increase the firing rates of this pro-
jection and consequently, elevate extracellular dopamine
levels in NA [13,14]. On the other hand, VTA is modu-
lated by GABAergic inputs [15,16]. GABAB receptors are
highly distributed in this area and inhibit VTA cell bodies,
i.e., when stimulated, hyperpolarize the membrane
potential and decrease firing rates of VTA neurons [17]. Xi
and Stein [10] have shown that systemic administration
of baclofen dose-dependently decreases heroin-induced
dopamine release in the NA and reduces the positive rein-
forcing properties of heroin. One the other hand, in nega-
tive reinforcement, the incentive for drug use is relief of a
painful or unpleasant state (i.e., negative affective symp-
toms of withdrawal such as dysphoria, depression, irrita-
bility and anxiety) [40]. Preclinical evidences suggest that
baclofen may reduce opioid withdrawal symptoms
[11,12]. Therefore, baclofen could be also useful in the
management of opioid dependence by attenuating with-
drawal symptoms and consequently, by reducing negative
reinforcing properties of opioids.
A few clinical studies have been conducted with baclofen
in cocaine, ethanol and nicotine users [1,18-20,38,39]
and one study has compared the efficacy of baclofen
The primary portion of brain reward circuitry appears to be a subset of dopaminergic projections originating in the ventral teg- mental area (VTA) and terminating in the nucleus accumbens (NA) Figure 1
The primary portion of brain reward circuitry appears to be a subset of dopaminergic projections originating in the ventral teg-
mental area (VTA) and terminating in the nucleus accumbens (NA). VTA is modulated by GABAergic inputs. GABAB receptors 
inhibit VTA cell bodies, i.e., when stimulated, hyperpolarize the membrane potential and decrease firing rates of VTA neurons.
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versus clonidine in acute detoxification of opioid depend-
ents [21]. However, while preclinical studies support the
idea that baclofen may help maintaining abstinence from
opioids via reducing both the positive reinforcing
(reward) properties [10,22] and negative reinforcement
(withdrawal) of opioids [11,12]; to the best of our knowl-
edge, there is no reported clinical trial that has evaluated
the efficacy of baclofen in maintenance therapy of opioid
dependence.
We conducted a randomized, double blind, placebo-con-
trolled, 12-week clinical trial to evaluate the possible ben-
efit of baclofen in the maintenance treatment of opioid
addicts. We primarily hypothesized that baclofen is supe-
rior to placebo in terms of retaining opioid addicts in the
maintenance treatment.
Methods
Subjects and setting
Subjects were eligible for the study if they met DSM-IV cri-
teria for opioid dependence [23], were detoxified at our
addiction clinic under the protocol discussed below, were
between 18 and 60 years of age, and gave written
informed consent for participation in the study. Subjects
were disqualified if they were pregnant or lactating; had
clinically serious unstable medical illness; were receiving
other medications; had a history of psychosis, mania or
severe major depression; reported concurrent dependency
to alcohol, cocaine or hallucinogens; had a history of anti-
social personality; or were mentally retarded.
Subjects were recruited from individuals seeking opioid
detoxification at the addiction clinic of Roozbeh Psychiat-
ric Hospital (the major psychiatric hospital affiliated with
Tehran University of Medical Sciences, Iran). Patients
could withdraw their participation at any time and trans-
fer to a conventional treatment. Those completing the
trial were also guaranteed transfer to a conventional treat-
ment (including naltrexone, individual counseling, and
weekly group psychotherapy with a focus on relapse pre-
vention). The study was conducted in accordance with the
Declaration of Helsinki and subsequent revisions and was
approved by the ethical committee at Tehran University of
Medical Sciences and by the research steering committee
at the psychiatric department of Tehran University of
Medical Sciences. Patient enrolment began in November
2001 and was completed in November 2002.
Detoxification phase
Once informed consent for detoxification was obtained,
subjects were detoxified in an outpatient setting with the
same treatment protocol lasting 2 weeks, including ther-
apy with clonidine, clonazepam and thioridazine. In the
last half of the detoxification period, all medications were
tapered and finally discontinued except for thioridazine,
which was permitted throughout the study in doses dis-
cussed below. At the end of the detoxification period, a
naloxone challenge test (subcutaneous injection of 0.8
mg of naloxone) was performed; patients with negative
results were considered successfully detoxified and were
eligible for the initiation of maintenance treatment.
Maintenance treatment phase
After giving written informed consent, detoxified subjects
entered a parallel group, randomized, double blind, fixed-
schedule, 12-week clinical trial. The clinical trial was con-
ducted in an outpatient setting. Subjects were randomly
assigned to treatment with baclofen or placebo, using a
computer-generated list of random numbers. A research
pharmacist prepared and dispensed all medications and
was the only person with knowledge of drug assignment.
The rater and patients remained blind to the treatment up
to the end of the study.
The initial daily dose of baclofen was 10 mg, increased to
60 mg (20 mg t.i.d.) over five days. The dose of 60 mg was
chosen in concordance with a clinical study that had eval-
uated baclofen for management of cocaine craving [18].
In order to preserve the double blind condition, baclofen
and placebo were dispensed in identical-appearing tablets
and all patients received 6 tablets daily in 3 divided doses.
Both groups received thioridazine 25–100 mg if needed at
night for management of insomnia. No other psycho-
tropic medication was prescribed. Subjects did not receive
any concomitant psychological treatment or psychosocial
support.
Patients were required to attend the clinic weekly to
receive their medication, complete measures, and provide
urine samples. The subjects who failed to attend one
appointment were encouraged by phone call to continue
treatment and were not excluded from the study for illicit
drug use. Patients were discharged from the study if they
1) missed two consecutive appointments or 2) used opio-
ids in doses as high as the amount used prior to the
detoxification for more than five consecutive days that led
to the necessity of their detoxification again. In these
cases, they were discharged from the study and referred for
the conventional treatments. Intermittent attendance was
tolerated.
Assessments
Patients were evaluated at the study entry with a psychiat-
ric history and semistructured interview that included a
DSM-IV diagnostic checklist. A medical history and phys-
ical examination were also performed. Moreover, demo-
graphic characteristics and other variables that could
influence the outcomes of maintenance therapy [24-26]
were recorded.BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/16
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Primary outcome variable was retention in treatment,
which was defined as the number of weeks that patients
remained in the study before being discharged. In addi-
tion, patients were examined weekly to determine use of
opioids, alcohol and other substances; opioid withdrawal
syndrome; and intensity of opioid craving. Substance use
was assessed by urinalysis and self-reports. Urine samples
were collected weekly and Thin Layer Chromatography
(TLC) was used to determine the presence of opiates.
Rates of opioid-positive urine tests were calculated for
each patient by dividing the number of opioid-positive
and missing urine specimens by the number of urine sam-
ples stipulated for the retention period. Self-report ratings
of drug and alcohol use were collected by an inventory
that was developed according to the reported items of the
Weekly Drug Use Inventory [27]. Subject were asked to
report the number of days during the past week that they
used opioids, alcohol or other illicit drugs; the routes of
administration used for each drugs; and the average
amount used each day in grams or rials (the unit of money
in Iran). Opioid craving was assessed with a visual ana-
logue scale (VAS). Patients expressed their level of craving
in the preceding week by making a mark on a 10 cm line,
ranging from no craving at one end to the most intensive
craving ever experienced at the other end. Opioid with-
drawal symptoms were assessed with the Short Opiate
Withdrawal Scale (SOWS) [28]. Every two weeks, depres-
sion was assessed with the Hamilton Depression Rating
Scale (HAM-D) [29] and adverse events were assessed sys-
tematically with a score sheet designed for the present
study. A third year resident of psychiatry (R. R.) who was
trained in the usage of the scales performed all clinical
research measurements.
Statistical analysis
Data analyses were conducted on the enrolled subjects
who met eligibility criteria for participation in the trial
(intention-to-treat analysis). Patients were compared for
socio-demographic variables by means of the chi-square
for categorical variables, and the t-test for continuous var-
iables. Associations between these variables and the pri-
mary outcome measure (retention in treatment) were
analyzed with the Cox's regression model. Retention rates
were assessed by the Kaplan-Meier method [30]. Kaplan-
Meier curves were compared using the log-rank test
[31,32]. Patients who completed the 12-week trial were
regarded as censored observation. Data on the SOWS,
HAM-D, opioid craving, and self-reports of opioids and
alcohol use were analyzed with repeated measures analy-
sis of variance (ANOVA), using treatment group as the
between-subjects factor and time as the within-subjects
variable. Missing data were replaced using a last-observa-
tion-carried-forward approach. Other outcome measures
were assessed by the chi-square and t-tests, and Mann-
Whitney U-tests. The chi-square test was used to verify dif-
ferences in frequencies. Mean value comparisons were
conducted after verifying the distribution of data; para-
metrically, using the unpaired t-test, or using the Mann-
Whitney U-test for non-Gaussian distributions.
Frequencies were assessed in absolute and relative terms
and data on interval scale levels were described using
mean values and standard deviation. All statistical tests
were two-sided, and were considered significant at P <
0.05.
Results
Sample characteristics
Eighty-seven patients initiated the detoxification but only
40 of them began the maintenance treatment. Reasons for
withdrawal of participation were premature termination
of detoxification (5), diagnosis of interfering medical or
psychiatric illnesses (9) and consent withdrawal (33) (Fig.
2).
Characteristics of study sample are shown in Table 1. The
two treatment groups did not differ significantly in the
majority of the socio-demographic and clinical variables
investigated at the baseline. The only significant
Trial profile Figure 2
Trial profile
87 Patients began detoxification
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40 randomized
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difference observed was in the number of previous absti-
nences (t = 2.32, P = 0.02). Since an association between
this variable and the primary outcome measure under
investigation (retention in treatment) was not found
(Wald statistics = 0.57, P = 0.45), it was not included as a
covariate in the following analyses.
Retention in treatment
Survival curves for the two groups are shown in Fig. 3.
Retention in treatment was significantly better in the
baclofen group (log-rank = 5.80, P  = 0.01). Subjects
treated with baclofen were retained in the study for longer
(55.3 ± 21.9 days) than the placebo-treated subjects (36.4
± 22.1 days) (t = 2.72, P = 0.01). Mann-Whitney U-test
also showed that patients from the baclofen group com-
pleted significantly more weeks (U = 99.50, P = 0.00).
The study was completed by 30% of patients from the
baclofen group versus 10% from the placebo group. Rea-
sons for dropping out from the trial differed in the two
groups. In the group that took baclofen, the treatment of
12 patients (60%) was interrupted due to missing of ≥ 2
consecutive appointments and in two others (10%), inter-
ruption was due to persistent use of opioids which
required detoxification. In the group that took placebo,
the treatment of 12 patients (60%) was similarly inter-
rupted due to missing of ≥ 2 consecutive appointments;
however, 6 patients (30%) dropped out due to persistent
use of opioids which required detoxification. No patients
in neither of the treatment groups reported adverse effects
that required dose reduction or termination from the
study; moreover, no statistically significant differences
were found between the two groups regarding the
reported adverse effects (Mann-Whitney U  = 179, P  =
0.57).
Effects on substance use
The rates of opioid-positive urine samples did not differ
significantly between the two groups: 76.9% ± 24.3% and
75.8% ± 24.3% for patients treated with baclofen and pla-
cebo, respectively (Mann-Whitney U = 191.5, P = 0.82).
Overall, there was a significant increase in the self-
reported days per week using opioids over time (F  =
13.54, P = 0.00) with linear trend (F = 20.00, P = 0.00) but
no significant difference between the two groups (F  =
1.63, P = 0.20) and no significant interaction between
treatment group and time (F = 1.21, P = 0.27) were seen.
However, as shown in Fig. 4, the baclofen group exhibited
a trend toward gentler slope of increase and the two
groups appeared to diverge over weeks. Nearly similar
pattern was observed with self-reports of alcohol con-
sumption. There was a significant main effect of time (F =
1.95, P = 0.03) but both the main effect of treatment and
the interaction of treatment and time were not significant
(F = 0.85, P = 0.36 and F = 0.39, P = 0.95; respectively).
Other outcomes
Overall, there was no significant difference between the
two groups on opioid craving scores. Although the main
effect of time was significant (F = 4.68, P = 0.00), there
Table 1: Baseline characteristics of 40 patients with DSM-IV opioid dependence randomly assigned to receive baclofen or placebo.
Variable Baclofen (N = 20) Placebo (N = 20)
M e a nS D M e a nS D
Age (years) 35.1 10.9 31.8 6.5
Age of onset of opioid use 23.2 6.2 21.0 4.9
Duration of opioid use (years) 8.8 6.2 7.0 4.9
Number of previous abstinences 3.7 2.2 2.2 1.9
Duration of the longest previous abstinence (months) 4.4 5.5 4.1 5.6
Income per month (Rials/10000) 81.7 69.3 99.5 103.7
N%N%
Sex (male) 20 100 20 100
Married 14 70 10 50
College education 2 10 2 10
Employed 14 70 10 50
Substance use in patient's family 13 65 17 85
Type of opioid
Heroin 73 5 63 0
Opium 13 65 14 70
Route of opioid use
Inhalation or ingestion 12 60 10 50
Injection or multiple routes 84 0 1 0 5 0
Psychiatric illness 5 25 8 40
Medical illness 1 5 0 0BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/16
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was no significant main effect of treatment or treatment-
by-time interaction (F = 1.45, P = 0.23 and F = 0.64, P =
0.78; respectively). Yet, the VAS scores were generally
lower in the baclofen group. Average scores on the VAS
were 37.1 ± 20.2 for the baclofen group compared to 43.7
± 25.3 for the placebo group.
Changes in intensity of the SOWS scores over time during
treatment with baclofen and placebo are shown in Fig. 5.
The repeated measure ANOVA showed that decrease in
the SOWS scores was significantly more pronounce in the
baclofen group. There was a significant main effect of
treatment (F = 9.45, P = 0.00) and time (F = 26.10, P =
0.00) but no significant interaction between time and
treatment was noted (F = 1.42, P = 0.16).
Baclofen was also statistically superior to placebo on the
HAM-D ratings (Fig. 6). There was a significant main
effect of treatment (F = 4.66, P = 0.03) and the main effect
of time and treatment-by-time interaction were also sig-
nificant (F  = 15.90, P  = 0.00 and F  = 4.45, P  = 0.00;
respectively).
Discussion
This report provides data from what we believe is the first
randomized, double blind, placebo-controlled clinical
trial evaluating the efficacy of baclofen in the mainte-
nance treatment of opioid dependence. Results showed
that baclofen is significantly superior to placebo in terms
of retention in treatment, opiate withdrawal syndrome,
and depressive symptoms. Additionally, baclofen showed
generally favorable responses along other outcome meas-
ures including opioid craving and self-reported opioid
and alcohol use; however, the differences were not signif-
icant. This study failed to show any effects for baclofen
over placebo with regard to urinalysis. The failure to find
Percentage of patients in each group who remained in treatment Figure 3
Percentage of patients in each group who remained in treatment.
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any significant difference in these measures may be due to
the small sample size; for example, there was limited sta-
tistical power to detect a difference among the treatment
groups on the VAS scores (observed power = 0.21), the
self-reported opioid use (observed power = 0.24) and
alcohol use (observed power = 0.06). Furthermore, opioid
urinalysis was performed weekly and by means of visual
evaluation of TLC. In other words, it was performed less
frequently and evaluated by less reliable method com-
pared to other studies (e.g. ref. [27,33,34]).
The findings of the present study cannot be readily com-
pared with those of other studies because no previous
clinical trials have evaluated the efficacy of baclofen in the
maintenance therapy of opioid dependence. Yet, our
results are consistent with the findings of previous preclin-
ical studies that support the idea that baclofen may be use-
ful in the treatment of opioid dependence [10-12,22].
This study may also give some insights about the
baclofen's mechanism of action in the management of
opioid dependence. Fewer withdrawal symptoms and
lower depression ratings in the baclofen group support
the idea that baclofen could reduce negative reinforcing
effects of opioids; however, non-significant differences in
opioid use and craving failed to provide evidence for the
efficacy of baclofen in attenuating opioid-associated pos-
itive reinforcement.
Attrition rates in our study were nearly twice the rates
reported by studies on methadone and buprenorphine
maintenance treatments [27,33,35,36]. However, benefi-
cial effects of the maintenance treatments for opioid
dependence have commonly been tested in individuals
who receive extensive psychological treatment and psy-
Self-reported days of opioid use per week during the 12 weeks of maintenance treatment with baclofen and placebo Figure 4
Self-reported days of opioid use per week during the 12 weeks of maintenance treatment with baclofen and placebo.
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chosocial support (e.g. ref. [27,33,34]), whereas in our
study, subjects did not receive any concomitant psycho-
logical treatment or psychosocial support. Interestingly,
in a recent study, buprenorphine without any additional
support has shown nearly similar retention rates [37].
In addition to the small sample size and limited statistical
power on some outcome measures, two other factors limit
the interpretation of these data. First, The external validity
or generalisability of our findings might be limited by
possible differences in patients' characteristics and other
local factors. For example, a high prevalence of concomi-
tant cocaine use or dependence seems common in some
other countries, but this pattern of codependence is
almost non-existent in Iran. Second, the high drop out
rate, especially beyond the first half of the trial, threatens
the internal validity of the study. Therefore, further studies
with larger numbers of patients receiving manual-guided
relapse prevention program and psychosocial support are
needed to verify the results of this study.
Conclusions
The results of this study provide evidence to support the
hypothesis that baclofen may be of some use in opioid
maintenance treatment. However, larger studies are
warranted.
Mean Short Opiate Withdrawal Scale (SOWS) scores during the 12 weeks of maintenance treatment with baclofen and  placebo Figure 5
Mean Short Opiate Withdrawal Scale (SOWS) scores during the 12 weeks of maintenance treatment with baclofen and 
placebo.
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